Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis

Jean Carruthers, Kenneth Beer, Alastair Carruthers, William P Coleman 3rd, Zoe Diana Draelos, Derek Jones, Mitchel P Goldman, Michael L Pucci, Amanda VanDenburgh, Emily Weng, Scott M Whitcup, Jean Carruthers, Kenneth Beer, Alastair Carruthers, William P Coleman 3rd, Zoe Diana Draelos, Derek Jones, Mitchel P Goldman, Michael L Pucci, Amanda VanDenburgh, Emily Weng, Scott M Whitcup

Abstract

Background: Eyebrow loss may have substantial negative functional and social consequences.

Objective: Evaluate the safety and efficacy of bimatoprost 0.03% in subjects with eyebrow hypotrichosis.

Methods: This multicenter, double-masked study randomized adult females or males with eyebrow hypotrichosis to receive bimatoprost 0.03% twice (BID) or once daily (QD) or vehicle BID for 7 months. Primary endpoint was overall eyebrow fullness at Month 7. Secondary endpoints included eyebrow fullness (mm), darkness (intensity units), and subject satisfaction with treatment. Safety was also assessed.

Results: At Month 7, the proportion of subjects with improvement was significantly higher in bimatoprost groups versus vehicle (both, p < .001). Improvements occurred in both bimatoprost groups versus vehicle after Month 1 and continued through follow-up; eyebrow fullness and darkness improved as early as Months 2 and 1, respectively (both, p < .001). Greater satisfaction was reported with bimatoprost versus vehicle at Month 2 and all subsequent time points. Overall, 38.1%, 42.4%, and 35.5% of subjects in the bimatoprost BID, QD, and vehicle groups, respectively, experienced ≥1 treatment-emergent adverse event (TEAE). Most frequent TEAEs were similar across groups. No skin or iris hyperpigmentation or conjunctival hyperemia occurred.

Conclusion: Bimatoprost 0.03% BID and QD is safe, well tolerated, and effective for eyebrow hypotrichosis.

Conflict of interest statement

The authors have indicated no significant interest with commercial supporters.

Figures

Figure 1
Figure 1
Disposition of subjects.
Figure 2
Figure 2
Percentage of subjects with at least a 1-grade improvement from baseline in GEBA by visit (intent-to-treat population). *p < .05 versus vehicle. †p < .001 versus vehicle. Bim, bimatoprost.
Figure 3
Figure 3
Examples of GEBA changes over time representative of the three treatment groups. One subject receiving bimatoprost BID (A) and one receiving QD (B) had GEBA grades of 2 (sparse) at baseline, 3 (full) at Month 4, and 4 (very full) at Month 7. The subject receiving vehicle (C) had a GEBA grade of 1 (very sparse) at baseline and 2 (sparse) at Months 4 and 7.
Figure 4
Figure 4
Improvement from baseline in eyebrow fullness (A) and eyebrow darkness (B) by visit (intent-to-treat population). Bim, bimatoprost.
Figure 5
Figure 5
Percentage of subjects who reported very satisfied/mostly satisfied on ESS Item 6 by visit (intent-to-treat population). *p < .05 versus vehicle for composite “very satisfied” and “mostly satisfied.” †p < .001 versus vehicle for composite very satisfied and mostly satisfied. Bim, bimatoprost.

References

    1. Baker SB, Dayan JH, Crane A, Kim S. The influence of brow shape on the perception of facial form and brow aesthetics. Plast Reconstr Surg 2007;119:2240–7.
    1. Sadr J, Jarudi I, Sinha P. The role of eyebrows in face recognition. Perception 2003;32:285–93.
    1. van der Velden EM, Drost BH, Ijsselmuiden OE, Baruchin AM, et al. Dermatography as a new treatment for alopecia areata of the eyebrows. Int J Dermatol 1998;37:617–21.
    1. Velez N, Khera P, English JC., III Eyebrow loss: clinical review. Am J Clin Dermatol 2007;8:337–46.
    1. Ortiz AE, Alster TS. Rising concern over cosmetic tattoos. Dermatol Surg 2012;38:424–9.
    1. Fitzpatrick RE, Goldman MP, Dierickx C. Laser ablation of facial cosmetic tattoos. Aesthet Plast Surg 1994;18:91–8.
    1. Women's Rogaine [package insert]. Skillman, NJ: Johnson & Johnson Healthcare Products; 2014.
    1. Jones D. Enhanced eyelashes: prescription and over-the-counter options. Aesthet Plast Surg 2011;35:116–21.
    1. Schweiger ES, Pinchover L, Bernstein RM. Topical bimatoprost for the treatment of eyebrow hypotrichosis. J Drugs Dermatol 2012;11:106–8.
    1. Vergilis-Kalner IJ. Application of bimatoprost ophthalmic solution 0.03% for the treatment of eyebrow hypotrichosis: series of ten cases. Dermatol Online J 2014;20.
    1. Beer KR, Julius H, Dunn M, Wilson F. Treatment of eyebrow hypotrichosis using bimatoprost: a randomized, double-blind, vehicle-controlled pilot study. Dermatol Surg 2013;39:1079–87.
    1. Smid SD. Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: a closer look at the agonist properties of bimatoprost and the prostamides. Clin Ophthalmol 2009;3:663–70.
    1. Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol 2008;153:410–9.
    1. Tauchi M, Fuchs TA, Kellenberger AJ, Woodward DF, et al. Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost. Br J Dermatol 2010;162:1186–97.
    1. Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg 2010;36:1361–71.
    1. Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol 2010;4:349–58.
    1. Fagien S. Management of hypotrichosis of the eyelashes: Focus on bimatoprost. Clin Cosmet Investig Dermatol 2010;3:39–48.
    1. Kapur R, Osmanovic S, Toyran S, Edward DP. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol 2005;123:1541–6.
    1. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985;41:55–68.
    1. Lee S, Tanglertsampan C, Tanchotikul M, Worapunpong N. Minoxidil 2% lotion for eyebrow enhancement: a randomized, double-blind, placebo-controlled, spilt-face comparative study. J Dermatol 2014;41:149–52.
    1. Suwanchatchai W, Tanglertsampan C, Pengsalae N, Makornwattana M. Efficacy and safety of bimatoprost 0.03% versus minoxidil 3% in enhancement of eyebrows: a randomized, double-blind, split-face comparative study. J Dermatol 2012;39:865–6.
    1. Williams RD, Cohen JS, Gross RL, Liu CC, et al. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol 2008;92:1387–92.
    1. Yoelin S, Walt JG, Earl M. Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth. Dermatol Surg 2010;36:638–49.
    1. Smith S, Fagien S, Whitcup SM, Ledon F, et al. Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol 2012;66:801–6.
    1. Harii K, Arase S, Tsuboi R, Weng E, et al. Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies. Aesthet Plast Surg 2014;38:451–60.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe